Chronic liver disease is an extremely common disease. It is caused by a variety of factors, including a faulty gene that regulates iron absorption. It also has a range of symptoms, including elevated portal pressure and esophageal and gastric varices. The most severe complication of CLD is esophageal variceal bleeding, and other complications include ascites and cirrhosis.
Liver disease can be very painful and is often accompanied by other symptoms, including aches and pains. If left untreated, this condition can cause the liver to become scarred, preventing blood flow to other organs. It also makes the healthy parts of the liver work harder. As a result, people with chronic liver disease may experience muscle weakness, itching, and weight loss, and may even develop kidney failure. Further, people with liver disease are at increased risk of developing diabetes, hypertension, and high cholesterol.
Middle East and Turkey chronic liver disease (CLD) therapeutics market size is estimated to be valued at US$ 1,015 million in 2021 and is expected to exhibit a CAGR of 5.8% over the forecast period (2022-2028).
Request Here PDF Brochure Of This Report @ https://www.coherentmarketinsights.com/insight/request-pdf/4920
The growing prevalence of chronic liver diseases such as nonalcoholic fatty liver disease, hepatitis, and others, among large population base in the Middle East region due to lifestyle diseases such as obesity and type 2 diabetes mellitus (DM) and this is projected to drive demand for drugs used in liver disease treatment, thereby propelling the market growth.
Chemotherapy Drugs segment is expected to hold largest market share in the Middle East and Turkey chronic liver disease (CLD) therapeutics market
Since cancer cells grow and multiply much faster than most of the cells in body, chemotherapy is most often utilized for cancer treatment. The increasing incidence of liver cancer and launch of novel products for cancer treatment are some of the factors, which are expected to drive the Chemotherapy Drugs segment growth. According to the International Agency for Research on Cancer (IARC), age-standardized incidence rate (ASIR) for liver cancer was 4.5 per 100,000 people in 2018 in Saudi Arabia.
Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Restraint
High cost of treatment for chronic liver diseases is expected to hinder the market growth. Furthermore, due to this factor, a large patient pool suffering from CLD is unable to avail proper treatment. The treatment for chronic liver diseases include chemotherapy, targeted therapy, vaccines, immunoglobulin, and others, which are overpriced for the patients in low and middle income countries in the (Middle East and North Africa) MENA region. For instance, the cost of surgical treatment of liver cancer in Herzliya Medical Center, Israel, is US$ 25,000 and the cost of chemotherapy starts at US$ 3,500.
Request Here For The Sample Copy Of The Report @ https://www.coherentmarketinsights.com/insight/request-sample/4920
Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market – Impact of Coronavirus (Covid-19) Pandemic
Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19, as pandemic on March 11, 2020. According to the Coronavirus (COVID-19), Weekly Epidemiological Update by the World Health Organization, over 263,563,622 cases and 5,232,562 deaths due to coronavirus disease (COVID-19) were reported till December 03, 2021, across the globe.
Treatment options for cancer such as chemotherapy can weaken the immune system of cancer patients and increase the risk of getting infected. Hence, people suffering from cancer such as liver cancer are at higher risk of developing serious complications due to COVID-19 infection.
Moreover, healthcare providers are adopting telehealth solutions to conduct their services for patients with severe chronic liver disease while maintaining social distancing to combat COVID-19 pandemic without compromising the health of patients with chronic liver disease. Patients can arrange virtual appointments with their doctors for consultations. Healthcare providers are taking above mentioned measures to reduce the spread of COVID-19 infection.
Furthermore some studies also indicated that, COVID-19 was significantly associated with alcoholic liver damage. Nevertheless, impact of alcohol during COVID-19 within the alcohol consumption and ALD may impact COVID-19 pathogenesis.
Major players operating in the Middle East and Turkey chronic liver disease (CLD) therapeutics market include Hoffmann-La Roche AG, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Swedish Orphan Biovitrum AB, GlaxoSmithKline Plc, Sanofi S.A, Merck & Co., Inc., AbbVie Inc., Abbott Laboratories, AstraZeneca plc, and Pfizer Inc.
Direct Buy This Premium Research Report, Click Here @ https://www.coherentmarketinsights.com/insight/buy-now/4920
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Industry Impact
Chapter 2 Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Competition by Types, Applications, and Top Regions and Countries
2.1 Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market (Volume and Value) by Type
2.3 Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 Company Profiles and Key Figures in Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Business
Chapter 6 Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Market Forecast (2022-2028)
Chapter 7 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027